- Home
- OBT vs TNXP Comparison
OBT vs TNXP Comparison
Compare OBT & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBT
- TNXP
- Stock Information
- Founded
- OBT 1892
- TNXP 2007
- Country
- OBT United States
- TNXP United States
- Employees
- OBT N/A
- TNXP N/A
- Industry
- OBT Major Banks
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- OBT Finance
- TNXP Health Care
- Exchange
- OBT Nasdaq
- TNXP Nasdaq
- Market Cap
- OBT 368.1M
- TNXP 335.6M
- IPO Year
- OBT N/A
- TNXP N/A
- Fundamental
- Price
- OBT $25.78
- TNXP $27.66
- Analyst Decision
- OBT Buy
- TNXP Buy
- Analyst Count
- OBT 1
- TNXP 1
- Target Price
- OBT $29.00
- TNXP $70.00
- AVG Volume (30 Days)
- OBT 30.5K
- TNXP 1.6M
- Earning Date
- OBT 10-29-2025
- TNXP 11-11-2025
- Dividend Yield
- OBT 1.97%
- TNXP N/A
- EPS Growth
- OBT N/A
- TNXP N/A
- EPS
- OBT 2.57
- TNXP N/A
- Revenue
- OBT $105,510,000.00
- TNXP $9,831,000.00
- Revenue This Year
- OBT $18.44
- TNXP $21.19
- Revenue Next Year
- OBT $6.40
- TNXP $722.94
- P/E Ratio
- OBT $10.29
- TNXP N/A
- Revenue Growth
- OBT 2.48
- TNXP N/A
- 52 Week Low
- OBT $20.97
- TNXP $6.76
- 52 Week High
- OBT $33.06
- TNXP $130.00
- Technical
- Relative Strength Index (RSI)
- OBT 51.67
- TNXP 47.82
- Support Level
- OBT N/A
- TNXP N/A
- Resistance Level
- OBT $26.68
- TNXP $31.55
- Average True Range (ATR)
- OBT 0.64
- TNXP 2.03
- MACD
- OBT -1.01
- TNXP -0.82
- Stochastic Oscillator
- OBT 95.41
- TNXP 82.26
About OBT Orange County Bancorp Inc.
Orange County Bancorp Inc provides banking services. Its services include personal banking services such as personal loans, personal savings, business loans, business savings, and Internet banking among others. The company provides commercial and consumer banking services to individuals, small businesses, and local municipal governments as well as trust and investment services through the Bank and HVIA. Its segment includes banking and wealth management. The company generates maximum revenue from the banking segment.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.